A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting

被引:92
作者
Liu, JK
Tenga, QS
Garrity-Moses, M
Federici, T
Tanase, D
Imperiale, MJ
Boulis, NM
机构
[1] Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Ctr Neurol Restorat, Cleveland, OH 44195 USA
[3] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA
关键词
dorsal root ganglion; ganglioside; motor neuron; phage display; tetanus toxin C fragment;
D O I
10.1016/j.nbd.2005.01.022
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A novel peptide with the binding characteristics of tetanus toxin was identified with phage display, for application in therapeutic protein and vector motor and sensory neuron targeting. A 12mer phage library was biopanned on trisialoganglioside (G(T1b)) and eluted with the tetanus toxin C fragment (rTTC). Phage ELISAs revealed increases in G(T1b) binding for the Tet1 and Tet2 phage clones when compared to peptideless phage (PLP). rTTC displaced both Tet1 and Tet2 phage clones from G(T1b), and both clones reduced rTTC-G(T1b) binding. Comparison of Tet1, Tet2, PLP, and the random phage library binding to PC12 and REK293 cells revealed enhanced cellular binding by Teti and Tet2 phage. Tell phage binding was selective for neurons. Immunolluorescence also confirmed selective PC12 binding of Tell and Tet2 phage. Fluorescein-conjugated synthetic Tet1, but not Tet2, peptide showed strong binding to cultured PC12, primary motor neurons, and dorsal root ganglion (DRG) cells. Synthetic Teti bound DRG and motor neurons but not muscle in tissue sections. The enhanced neuronal binding affinity and specificity of Tet1, a novel 12 amino acid peptide, suggests potential utility for targeting neurotherapeutic proteins and viral vectors in the treatment of motor neuron disease, neuropathy, and pain. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:407 / 418
页数:12
相关论文
共 63 条
[1]   Recombinant adeno-associated virus type 2 mediates highly efficient gene transfer in regenerating rat skeletal muscle [J].
Abadie, J ;
Blouin, V ;
Guigand, L ;
Wyers, M ;
Cherel, Y .
GENE THERAPY, 2002, 9 (15) :1037-1043
[2]   Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases [J].
Alisky, JM ;
Davidson, BL .
HUMAN GENE THERAPY, 2000, 11 (17) :2315-2329
[3]   Neurotrophic factor therapy - Prospects and problems [J].
Apfel, SC .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (04) :351-355
[4]  
ASKANAS V, 1995, ADV NEUROL, V68, P241
[5]   Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries [J].
Barry, MA ;
Dower, WJ ;
Johnston, SA .
NATURE MEDICINE, 1996, 2 (03) :299-305
[6]   Delayed application of IGF-1 and GDNF can rescue already injured postnatal motor neurons [J].
Bilak, MM ;
Kuncl, RW .
NEUROREPORT, 2001, 12 (11) :2531-2535
[7]   When biotoxins are tools of terror - Early recognition of intentional poisoning can attenuate effects [J].
Blazes, DL ;
Lawler, JV ;
Lazarus, AA .
POSTGRADUATE MEDICINE, 2002, 112 (02) :89-+
[8]   A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis [J].
Borasio, GD ;
Robberecht, W ;
Leigh, PN ;
Emile, J ;
Guiloff, RJ ;
Jerusalem, F ;
Silani, V ;
Vos, PE ;
Wokke, JHJ ;
Dobbins, T .
NEUROLOGY, 1998, 51 (02) :583-586
[9]   Clinical characteristics and management of ALS [J].
Borasio, GD ;
Miller, RG .
SEMINARS IN NEUROLOGY, 2001, 21 (02) :155-166
[10]  
BOULIS N, 2000, MOL THER, V1, pS110